C3BS inks preferred access agreement with Mayo Clinic Cardio3 BioSciences , a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, today the signing of a preferred access agreement with Mayo Clinic announces. Under this agreement, Mayo grants Cardio3 BioSciences chosen access to technologies developed in the Mayo Clinic Center for Regenerative Medicine, as well as select other Mayo technologies.D., Ph.D. At Mayo Clinic.Suicides were the just cause of loss of life that increased for children through age group 19 from 2003-04, monday according to a CDC record released. ‘This is very disturbing news,’ stated Dr. David Fassler, a University of Vermont psychiatry professor. He noted that the boost coincided with regulatory actions by the U.S. Food and Drug Administration that led to a black container warning on prescription packages cautioning that antidepressants could cause suicidal behavior in children. Fassler testified at FDA hearings on antidepressants during 2003 and 2004 and urged caution about implementing black box warnings. The agency purchased the warnings in October 2004 plus they began to appear on drug labels about six months later.